Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Total Debt (2019 - 2026)

Alx Oncology Holdings' Total Debt history spans 5 years, with the latest figure at $9.6 million for Q4 2023.

  • On a quarterly basis, Total Debt fell 12.68% to $9.6 million in Q4 2023 year-over-year; TTM through Dec 2023 was $9.6 million, a 12.68% decrease, with the full-year FY2023 number at $9.6 million, down 12.68% from a year prior.
  • Total Debt hit $9.6 million in Q4 2023 for Alx Oncology Holdings, up from $9.6 million in the prior quarter.
  • Over the last five years, Total Debt for ALXO hit a ceiling of $11.0 million in Q4 2022 and a floor of $3.0 million in Q4 2021.
  • Historically, Total Debt has averaged $7.3 million across 5 years, with a median of $5.8 million in 2020.
  • Biggest five-year swings in Total Debt: surged 264.32% in 2022 and later dropped 12.68% in 2023.
  • Tracing ALXO's Total Debt over 5 years: stood at $5.4 million in 2019, then rose by 6.25% to $5.8 million in 2020, then tumbled by 47.4% to $3.0 million in 2021, then surged by 264.32% to $11.0 million in 2022, then dropped by 12.68% to $9.6 million in 2023.
  • Business Quant data shows Total Debt for ALXO at $9.6 million in Q4 2023, $9.6 million in Q3 2023, and $9.5 million in Q2 2023.